DV
Dividend Vision

HALO — Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. (HALO)

Total return is 2277.3% over the past 22.4 years, 1335.7 points ahead of SPY at 941.6%. Its deepest 1-year drawdown was 24.1%.

HALO is a single-stock equity holding in Halozyme Therapeutics Inc., a biopharmaceutical company, rather than a diversified ETF. As a concentrated equity position, it does not have a dividend distribution rate or yield profile typical of dividend-focused ETFs. This holding appeals primarily to growth-oriented investors seeking exposure to the biotechnology sector rather than income-focused investors.

HALO key facts

Asset type
Stock
Asset class
Equity
Inception date
03/12/2004
Distribution frequency
None
Last close
$98.66
Market cap
$11,197,713,408
Average volume
1658900.0
Beta
0.848
Payout ratio
0.0
P/E ratio
28.9326
Forward P/E
14.2045
EPS
$3.41